Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...
Scotiabank analyst Greg Harrison maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $310.00.
NICE' has said that Wainzua can be used as an alternative to Alnylam's Amvuttra (vutrisiran), which was recommended for NHS ...
Hosted on MSN17h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseAlnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s ...
Kaye, who has held positions at Genzyme and Sarepta Therapeutics — where he led development of the Duchenne muscular ...
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
This announcement is an abridged version of the Company’s Half Year Report for the six months ended 30 September 2024. This announcement contains references to graphs and charts which appear in the ...
Lockheed Martin has felt financial strain as early funding for the upcoming F-35 jets dried up, but kept working on them to avoid supply chain disruptions.
Netflix announced in April 2024 that it had officially ordered and put into production a new action thriller called Ad Vitam, which translates to To Life in English. The movie has since completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback